Long-lasting vaginal protection against HIV using mRNA technology
Durable Vaginal Protection from HIV via mRNA expression of BNABS
This study is testing a new way to help women prevent HIV infections by using a special delivery method to send protective antibodies directly to the female reproductive area, aiming to give women more control over their health, especially in places where other methods might not work as well.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10694091 on NIH RePORTER |
What this research studies
This research aims to develop a new method for preventing HIV infections in women by using synthetic mRNA to express broadly neutralizing antibodies (bnAbs) directly in the female reproductive tract. The approach involves aerosol delivery of mRNA, which has shown promise in providing durable protection against the virus in laboratory settings. By focusing on female-controlled prevention methods, this research seeks to empower women in their fight against HIV, especially in regions where traditional prevention methods may not be effective. The study builds on previous findings that demonstrated the potential of bnAbs to prevent HIV infection even after exposure.
Who could benefit from this research
Good fit: Ideal candidates for this research are women at risk of HIV infection, particularly those in regions with high rates of transmission.
Not a fit: Patients who are not at risk for HIV or those who are already HIV positive may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide women with a reliable and long-lasting method of HIV prevention that they can control.
How similar studies have performed: Previous research has shown success with similar approaches using bnAbs, but this specific method of mRNA delivery is novel and untested in humans.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Santangelo, Philip J — Emory University
- Study coordinator: Santangelo, Philip J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.